The rise of the FGFR inhibitor in advanced biliary cancer: The next cover of time magazine?

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Cholangiocarcinomas (CCAs) are heterogeneous tumors arising from the biliary tract with features of cholangiocyte differentiation. CCAs are aggressive tumors with limited treatment options and poor overall survival. Only a subset of CCA patients with early stage disease can avail potentially curative treatment options. For advanced biliary tract tumors, currently there are limited effective treatment modalities. Recent advances have provided greater insight into the genomic landscape of CCAs. The fibroblast growth factor receptor (FGFR) pathway is involved in key cellular processes essential to survival and differentiation. Accordingly, aberrant FGFR signaling has significant oncogenic potential. Recent discovery of FGFR2 gene fusions in CCA has heightened interest in FGFR inhibition in advanced biliary tract cancer. These findings have served as a catalyst for ongoing clinical investigation of FGFR inhibition in CCA patients with various FGFR signaling abnormalities. Herein, we review FGFR aberrations in CCA and their prognostic implications, FGFR targeting as a viable therapeutic option in advanced biliary tract malignancies, and future directions for development of combination approaches utilizing FGFR inhibition.

Original languageEnglish (US)
Pages (from-to)789-796
Number of pages8
JournalJournal of Gastrointestinal Oncology
Volume7
Issue number5
DOIs
StatePublished - Jan 1 2016

Fingerprint

Biliary Tract Neoplasms
Fibroblast Growth Factor Receptors
Cholangiocarcinoma
Biliary Tract
Neoplasms
Survival
Gene Fusion
Therapeutics

Keywords

  • Cholangiocarcinoma (CCA)
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

The rise of the FGFR inhibitor in advanced biliary cancer : The next cover of time magazine? / Rizvi, Sumera; Borad, Mitesh J.

In: Journal of Gastrointestinal Oncology, Vol. 7, No. 5, 01.01.2016, p. 789-796.

Research output: Contribution to journalReview article

@article{74a941c5bb154358b51cc47daf3c1e41,
title = "The rise of the FGFR inhibitor in advanced biliary cancer: The next cover of time magazine?",
abstract = "Cholangiocarcinomas (CCAs) are heterogeneous tumors arising from the biliary tract with features of cholangiocyte differentiation. CCAs are aggressive tumors with limited treatment options and poor overall survival. Only a subset of CCA patients with early stage disease can avail potentially curative treatment options. For advanced biliary tract tumors, currently there are limited effective treatment modalities. Recent advances have provided greater insight into the genomic landscape of CCAs. The fibroblast growth factor receptor (FGFR) pathway is involved in key cellular processes essential to survival and differentiation. Accordingly, aberrant FGFR signaling has significant oncogenic potential. Recent discovery of FGFR2 gene fusions in CCA has heightened interest in FGFR inhibition in advanced biliary tract cancer. These findings have served as a catalyst for ongoing clinical investigation of FGFR inhibition in CCA patients with various FGFR signaling abnormalities. Herein, we review FGFR aberrations in CCA and their prognostic implications, FGFR targeting as a viable therapeutic option in advanced biliary tract malignancies, and future directions for development of combination approaches utilizing FGFR inhibition.",
keywords = "Cholangiocarcinoma (CCA), Targeted therapy",
author = "Sumera Rizvi and Borad, {Mitesh J}",
year = "2016",
month = "1",
day = "1",
doi = "10.21037/jgo.2016.08.12",
language = "English (US)",
volume = "7",
pages = "789--796",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "5",

}

TY - JOUR

T1 - The rise of the FGFR inhibitor in advanced biliary cancer

T2 - The next cover of time magazine?

AU - Rizvi, Sumera

AU - Borad, Mitesh J

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Cholangiocarcinomas (CCAs) are heterogeneous tumors arising from the biliary tract with features of cholangiocyte differentiation. CCAs are aggressive tumors with limited treatment options and poor overall survival. Only a subset of CCA patients with early stage disease can avail potentially curative treatment options. For advanced biliary tract tumors, currently there are limited effective treatment modalities. Recent advances have provided greater insight into the genomic landscape of CCAs. The fibroblast growth factor receptor (FGFR) pathway is involved in key cellular processes essential to survival and differentiation. Accordingly, aberrant FGFR signaling has significant oncogenic potential. Recent discovery of FGFR2 gene fusions in CCA has heightened interest in FGFR inhibition in advanced biliary tract cancer. These findings have served as a catalyst for ongoing clinical investigation of FGFR inhibition in CCA patients with various FGFR signaling abnormalities. Herein, we review FGFR aberrations in CCA and their prognostic implications, FGFR targeting as a viable therapeutic option in advanced biliary tract malignancies, and future directions for development of combination approaches utilizing FGFR inhibition.

AB - Cholangiocarcinomas (CCAs) are heterogeneous tumors arising from the biliary tract with features of cholangiocyte differentiation. CCAs are aggressive tumors with limited treatment options and poor overall survival. Only a subset of CCA patients with early stage disease can avail potentially curative treatment options. For advanced biliary tract tumors, currently there are limited effective treatment modalities. Recent advances have provided greater insight into the genomic landscape of CCAs. The fibroblast growth factor receptor (FGFR) pathway is involved in key cellular processes essential to survival and differentiation. Accordingly, aberrant FGFR signaling has significant oncogenic potential. Recent discovery of FGFR2 gene fusions in CCA has heightened interest in FGFR inhibition in advanced biliary tract cancer. These findings have served as a catalyst for ongoing clinical investigation of FGFR inhibition in CCA patients with various FGFR signaling abnormalities. Herein, we review FGFR aberrations in CCA and their prognostic implications, FGFR targeting as a viable therapeutic option in advanced biliary tract malignancies, and future directions for development of combination approaches utilizing FGFR inhibition.

KW - Cholangiocarcinoma (CCA)

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85017549214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017549214&partnerID=8YFLogxK

U2 - 10.21037/jgo.2016.08.12

DO - 10.21037/jgo.2016.08.12

M3 - Review article

AN - SCOPUS:85017549214

VL - 7

SP - 789

EP - 796

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 5

ER -